Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267030 | 0.90 | ADRA2C (0.59) | ADRA2CSMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL1266365 | 0.89 | ALDH1A1 (0.58) | ADRA2CSMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL1267009 | 0.87 | ALDH1A1 (0.48) | ADRA2CSMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL1267260 | 0.83 | ADRA2C (0.58) | ADRA2CSMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL1266012 | 0.82 | ADRA2C (0.55) | ADRA2CSMN1; SMN2ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL1267017 | 0.81 | ALDH1A1 (0.53) | SMN1; SMN2MAPTALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL1266315 | 0.79 | ABL1 (0.46) | SMN1; SMN2MAPTALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL1266972 | 0.79 | ADRA2C (0.61) | ADRA2CSMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL1266067 | 0.79 | ADRA2C (0.58) | ADRA2CSMN1; SMN2MAPTALDH1A1L3MBTL1 | |
| SCHEMBL1266801 | 0.77 | KMT2A (0.52) | ADRA2CSMN1; SMN2MAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879858-B2 | monoamine reuptake inhibitors such as (3-fluorophenyl)(1-(2-methoxyphenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methanone, used as antidepressants, anxiolytic agents and analgesics | GRUENENTHAL GMBH (DE) | 2011-02-01 | — | — | US | claimed |
| US-20090258880-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in Pharmaceutical Compositions | GRUENENTHAL GMBH (DE) | 2009-10-15 | — | — | US | claimed |
| US-7879858-B2 | monoamine reuptake inhibitors such as (3-fluorophenyl)(1-(2-methoxyphenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methanone, used as antidepressants, anxiolytic agents and analgesics | GRUENENTHAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20090258880-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in Pharmaceutical Compositions | GRUENENTHAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258880-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in Pharmaceutical Compositions | DHPS, APC, CYP3A5 | ADRA2C 185/4885SMN1; SMN2 1583/4885MAPT 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.